Fonseca A, et al. - In this phase III, single-arm trial, researchers assessed 302 candidates to estimate the relapse detection methods among kids and adolescents with nongerminomatous malignant germ cell tumors (MGCTs) and also to determine the adequacy of tumor markers alone for surveillance. They noticed 7 candidates with normal tumor markers at initial diagnosis, and none of them experienced a relapse. About 98% of relapses were detected by tumor marker elevation after central review. They found that 64.6% of cases had abnormal tumor markers with abnormal imaging and one patient had abnormal imaging with unknown marker levels at relapse.